BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …

Background The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Background Some observational studies found that dyslipidaemia is a risk factor for non-
alcoholic fatty liver disease (NAFLD), and lipid-lowering drugs may lower NAFLD risk …

Drugs whose targets have genetic evidence to support efficacy and safety are more likely to
be approved after clinical development. In this paper, we provide an overview of how natural …

Background Blood pressure lowering is an established strategy for preventing microvascular
and macrovascular complications of diabetes, but its role in the prevention of diabetes itself …

Cerebral small vessel disease (cSVD) is a leading cause of ischaemic and haemorrhagic
stroke and a major contributor to dementia. Covert cSVD, which is detectable with brain MRI …

Downregulation of IL-6 (interleukin-6) signaling has been proposed as a strategy for
lowering cardiovascular risk. Secondary analyses from CANTOS (Canakinumab Anti …

Background: Recent clinical guidelines support intensive blood pressure treatment targets.
However, observational data suggest that excessive diastolic blood pressure (DBP) …

Background Epidemiological studies have reported conflicting findings on the potential
adverse effects of long-term antihypertensive medication use on cancer risk. Naturally …

Elucidating the causes of stroke is key to develo** effective preventive strategies. The
Mendelian randomization approach leverages genetic variants related to an exposure of …